AP
MLYS icon

Andera Partners’s Mineralys Therapeutics MLYS Stock Holding History

Andera Partners’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$40M Hold
1,591,917
– – 22.77% 2
2026
Q2 		$42.9M Hold
1,591,917
– – 20.8% 2
2026
Q1 		$43.1M Hold
1,591,917
– – 24.38% 3
2025
Q4 		$57.8M Buy
+1,591,917
New +$63.8M 32.71% 2

Other funds holding MLYS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
FIA
FNY Investment Advisers New York $402M AUM 85.34% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MassMutual Private Wealth & Trust
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
PWMG
Private Wealth Management Group Princeton, New Jersey $445M AUM 13.54% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Andera Partners's MLYS Position: Q3 2026 in Review

Andera Partners held its Mineralys Therapeutics (MLYS) position steady in Q3 2026 at 1,591,917 shares worth $40M. The position accounts for 22.77% of the portfolio, ranked #2.

Andera Partners first reported a position in MLYS in Q4 2025 and has held it in 4 quarters since. The position peaked at $57.8M in Q4 2025. 12 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.

  • Andera Partners held 1,591,917 shares of Mineralys Therapeutics worth $40M as of Q3 2026.
  • Andera Partners left its Mineralys Therapeutics share count unchanged in Q3 2026.
  • Mineralys Therapeutics made up 22.77% of Andera Partners's portfolio in Q3 2026, its #2 holding.
  • Andera Partners first reported a position in Mineralys Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Andera Partners's Mineralys Therapeutics position peaked at $57.8M in Q4 2025.
  • 12 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.

Based on Andera Partners's 13F filing for Q3 2026, filed 16 Oct 2026.